Efficacy and tolerability in migraine prophylaxis of flunarizine in reduced doses: A comparison with propranolol 160 mg daily

H. C. Diener, J. Matias-Guiu, E. Hartung, V. Pfaffenrath, H. P. Ludin, G. Nappi, F. De Beukelaar

Research output: Contribution to journalArticle

Abstract

This was a phase-IV double-blind equivalence trial designed to assess the efficacy and tolerability of two doses of flunarizine (10 mg o.d. = FLU 10 mg and 5 mg o.d. = FLU 5 mg) in the prophylaxis of migraine, in comparison with slow-release propranolol (160 mg o.d.). A total of 808 subjects were treated in a treatment period of 16 weeks. 142 subjects discontinued the trial prematurely, mainly because of adverse events (n = 58). The mean attack frequency in the double-blind period was 2.0 for the FLU 5 mg group, 1.9 for the FLU 10 mg group, and 1.9 for the propranolol group. The mean attack frequency in the last 28 days of the double-blind period was 1.8 for FLU 5 mg, 1.6 for FLU 10 mg, and 1.7 for propranolol. Both flunarizine groups were at least as effective as propranolol (P <0.001 in one-sided test). The percentage of responders (defined as subjects for whom attack frequency decreased by at least 50% compared to run-in) in the last 28 days of the double-blind period was 46% (118/259) for FLU 5 mg, 53% (141/264) for FLU 10 mg, and 48% (125/258) for propranolol. Statistical analysis showed that FLU 10 mg is at least as effective as propranolol (P<0.001) and showed a trend for noninferiority of FLU5 and propranolol (P = 0.053). No statistically significant differences between the treatment groups were found for any of the secondary parameters. Overall, 190 subjects reported one or more adverse events during the run-in phase: 54 (20.5%) in the FLU 5 mg group, 76 (27.7%) in the FLU 10 mg group and 60 (22.3%) in the propranolol group. The results of this equivalence trial show that 10 mg flunarizine daily with a drug-free weekend is at least as effective as 160 mg propranolol in the prophylaxis of migraine for all evaluated parameters (one-sided equivalence tests) after 16 weeks of treatment. In addition, 5 mg flunarizine proves to be at least as effective as 160 mg propranolol when looking at the mean attack frequency for both the whole double-blind period and the last 28 days of treatment. However, in the analysis of responders, 160 mg propranolol seems to be slightly better than 5 mg flunarizine. In addition, no significant differences between the three treatments were found with regard to safety: all three treatments were generally well-tolerated and safe.

Original languageEnglish
Pages (from-to)209-221
Number of pages13
JournalCephalalgia
Volume22
Issue number3
DOIs
Publication statusPublished - 2002

Fingerprint

Flunarizine
Migraine Disorders
Propranolol

Keywords

  • Flunarizine
  • Migraine
  • Migraine prophylaxis
  • Propranolol

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Diener, H. C., Matias-Guiu, J., Hartung, E., Pfaffenrath, V., Ludin, H. P., Nappi, G., & De Beukelaar, F. (2002). Efficacy and tolerability in migraine prophylaxis of flunarizine in reduced doses: A comparison with propranolol 160 mg daily. Cephalalgia, 22(3), 209-221. https://doi.org/10.1046/j.1468-2982.2002.t01-1-00309.x

Efficacy and tolerability in migraine prophylaxis of flunarizine in reduced doses : A comparison with propranolol 160 mg daily. / Diener, H. C.; Matias-Guiu, J.; Hartung, E.; Pfaffenrath, V.; Ludin, H. P.; Nappi, G.; De Beukelaar, F.

In: Cephalalgia, Vol. 22, No. 3, 2002, p. 209-221.

Research output: Contribution to journalArticle

Diener, HC, Matias-Guiu, J, Hartung, E, Pfaffenrath, V, Ludin, HP, Nappi, G & De Beukelaar, F 2002, 'Efficacy and tolerability in migraine prophylaxis of flunarizine in reduced doses: A comparison with propranolol 160 mg daily', Cephalalgia, vol. 22, no. 3, pp. 209-221. https://doi.org/10.1046/j.1468-2982.2002.t01-1-00309.x
Diener, H. C. ; Matias-Guiu, J. ; Hartung, E. ; Pfaffenrath, V. ; Ludin, H. P. ; Nappi, G. ; De Beukelaar, F. / Efficacy and tolerability in migraine prophylaxis of flunarizine in reduced doses : A comparison with propranolol 160 mg daily. In: Cephalalgia. 2002 ; Vol. 22, No. 3. pp. 209-221.
@article{2825c908bde7405d81b5447b8a0593b5,
title = "Efficacy and tolerability in migraine prophylaxis of flunarizine in reduced doses: A comparison with propranolol 160 mg daily",
abstract = "This was a phase-IV double-blind equivalence trial designed to assess the efficacy and tolerability of two doses of flunarizine (10 mg o.d. = FLU 10 mg and 5 mg o.d. = FLU 5 mg) in the prophylaxis of migraine, in comparison with slow-release propranolol (160 mg o.d.). A total of 808 subjects were treated in a treatment period of 16 weeks. 142 subjects discontinued the trial prematurely, mainly because of adverse events (n = 58). The mean attack frequency in the double-blind period was 2.0 for the FLU 5 mg group, 1.9 for the FLU 10 mg group, and 1.9 for the propranolol group. The mean attack frequency in the last 28 days of the double-blind period was 1.8 for FLU 5 mg, 1.6 for FLU 10 mg, and 1.7 for propranolol. Both flunarizine groups were at least as effective as propranolol (P <0.001 in one-sided test). The percentage of responders (defined as subjects for whom attack frequency decreased by at least 50{\%} compared to run-in) in the last 28 days of the double-blind period was 46{\%} (118/259) for FLU 5 mg, 53{\%} (141/264) for FLU 10 mg, and 48{\%} (125/258) for propranolol. Statistical analysis showed that FLU 10 mg is at least as effective as propranolol (P<0.001) and showed a trend for noninferiority of FLU5 and propranolol (P = 0.053). No statistically significant differences between the treatment groups were found for any of the secondary parameters. Overall, 190 subjects reported one or more adverse events during the run-in phase: 54 (20.5{\%}) in the FLU 5 mg group, 76 (27.7{\%}) in the FLU 10 mg group and 60 (22.3{\%}) in the propranolol group. The results of this equivalence trial show that 10 mg flunarizine daily with a drug-free weekend is at least as effective as 160 mg propranolol in the prophylaxis of migraine for all evaluated parameters (one-sided equivalence tests) after 16 weeks of treatment. In addition, 5 mg flunarizine proves to be at least as effective as 160 mg propranolol when looking at the mean attack frequency for both the whole double-blind period and the last 28 days of treatment. However, in the analysis of responders, 160 mg propranolol seems to be slightly better than 5 mg flunarizine. In addition, no significant differences between the three treatments were found with regard to safety: all three treatments were generally well-tolerated and safe.",
keywords = "Flunarizine, Migraine, Migraine prophylaxis, Propranolol",
author = "Diener, {H. C.} and J. Matias-Guiu and E. Hartung and V. Pfaffenrath and Ludin, {H. P.} and G. Nappi and {De Beukelaar}, F.",
year = "2002",
doi = "10.1046/j.1468-2982.2002.t01-1-00309.x",
language = "English",
volume = "22",
pages = "209--221",
journal = "Cephalalgia",
issn = "0333-1024",
publisher = "SAGE Publications Ltd",
number = "3",

}

TY - JOUR

T1 - Efficacy and tolerability in migraine prophylaxis of flunarizine in reduced doses

T2 - A comparison with propranolol 160 mg daily

AU - Diener, H. C.

AU - Matias-Guiu, J.

AU - Hartung, E.

AU - Pfaffenrath, V.

AU - Ludin, H. P.

AU - Nappi, G.

AU - De Beukelaar, F.

PY - 2002

Y1 - 2002

N2 - This was a phase-IV double-blind equivalence trial designed to assess the efficacy and tolerability of two doses of flunarizine (10 mg o.d. = FLU 10 mg and 5 mg o.d. = FLU 5 mg) in the prophylaxis of migraine, in comparison with slow-release propranolol (160 mg o.d.). A total of 808 subjects were treated in a treatment period of 16 weeks. 142 subjects discontinued the trial prematurely, mainly because of adverse events (n = 58). The mean attack frequency in the double-blind period was 2.0 for the FLU 5 mg group, 1.9 for the FLU 10 mg group, and 1.9 for the propranolol group. The mean attack frequency in the last 28 days of the double-blind period was 1.8 for FLU 5 mg, 1.6 for FLU 10 mg, and 1.7 for propranolol. Both flunarizine groups were at least as effective as propranolol (P <0.001 in one-sided test). The percentage of responders (defined as subjects for whom attack frequency decreased by at least 50% compared to run-in) in the last 28 days of the double-blind period was 46% (118/259) for FLU 5 mg, 53% (141/264) for FLU 10 mg, and 48% (125/258) for propranolol. Statistical analysis showed that FLU 10 mg is at least as effective as propranolol (P<0.001) and showed a trend for noninferiority of FLU5 and propranolol (P = 0.053). No statistically significant differences between the treatment groups were found for any of the secondary parameters. Overall, 190 subjects reported one or more adverse events during the run-in phase: 54 (20.5%) in the FLU 5 mg group, 76 (27.7%) in the FLU 10 mg group and 60 (22.3%) in the propranolol group. The results of this equivalence trial show that 10 mg flunarizine daily with a drug-free weekend is at least as effective as 160 mg propranolol in the prophylaxis of migraine for all evaluated parameters (one-sided equivalence tests) after 16 weeks of treatment. In addition, 5 mg flunarizine proves to be at least as effective as 160 mg propranolol when looking at the mean attack frequency for both the whole double-blind period and the last 28 days of treatment. However, in the analysis of responders, 160 mg propranolol seems to be slightly better than 5 mg flunarizine. In addition, no significant differences between the three treatments were found with regard to safety: all three treatments were generally well-tolerated and safe.

AB - This was a phase-IV double-blind equivalence trial designed to assess the efficacy and tolerability of two doses of flunarizine (10 mg o.d. = FLU 10 mg and 5 mg o.d. = FLU 5 mg) in the prophylaxis of migraine, in comparison with slow-release propranolol (160 mg o.d.). A total of 808 subjects were treated in a treatment period of 16 weeks. 142 subjects discontinued the trial prematurely, mainly because of adverse events (n = 58). The mean attack frequency in the double-blind period was 2.0 for the FLU 5 mg group, 1.9 for the FLU 10 mg group, and 1.9 for the propranolol group. The mean attack frequency in the last 28 days of the double-blind period was 1.8 for FLU 5 mg, 1.6 for FLU 10 mg, and 1.7 for propranolol. Both flunarizine groups were at least as effective as propranolol (P <0.001 in one-sided test). The percentage of responders (defined as subjects for whom attack frequency decreased by at least 50% compared to run-in) in the last 28 days of the double-blind period was 46% (118/259) for FLU 5 mg, 53% (141/264) for FLU 10 mg, and 48% (125/258) for propranolol. Statistical analysis showed that FLU 10 mg is at least as effective as propranolol (P<0.001) and showed a trend for noninferiority of FLU5 and propranolol (P = 0.053). No statistically significant differences between the treatment groups were found for any of the secondary parameters. Overall, 190 subjects reported one or more adverse events during the run-in phase: 54 (20.5%) in the FLU 5 mg group, 76 (27.7%) in the FLU 10 mg group and 60 (22.3%) in the propranolol group. The results of this equivalence trial show that 10 mg flunarizine daily with a drug-free weekend is at least as effective as 160 mg propranolol in the prophylaxis of migraine for all evaluated parameters (one-sided equivalence tests) after 16 weeks of treatment. In addition, 5 mg flunarizine proves to be at least as effective as 160 mg propranolol when looking at the mean attack frequency for both the whole double-blind period and the last 28 days of treatment. However, in the analysis of responders, 160 mg propranolol seems to be slightly better than 5 mg flunarizine. In addition, no significant differences between the three treatments were found with regard to safety: all three treatments were generally well-tolerated and safe.

KW - Flunarizine

KW - Migraine

KW - Migraine prophylaxis

KW - Propranolol

UR - http://www.scopus.com/inward/record.url?scp=0036259074&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036259074&partnerID=8YFLogxK

U2 - 10.1046/j.1468-2982.2002.t01-1-00309.x

DO - 10.1046/j.1468-2982.2002.t01-1-00309.x

M3 - Article

C2 - 12047461

AN - SCOPUS:0036259074

VL - 22

SP - 209

EP - 221

JO - Cephalalgia

JF - Cephalalgia

SN - 0333-1024

IS - 3

ER -